Ann: CHM 1101 data accepted for presentation at SNO meeting, page-119

I somehow suspect CHM are extending a courtesy to the SNO Conference, by not stealing any thunder from Christine Brown and her presentations and holding off on too many of their own presentations, stock commentator releases posts etc. More colour will be added after Friday. But, what we do know is - primary endpoints have been achieved in safety and great signs of efficacy in this very early stage are more than what we could have hoped for. You just cannot expect a partial response at a low dose of 10% of the planned dose in the final cohort. Especially as to achieve partial response in this trial you need less than 50% reduction of tumour, thats just that's massive. With the next cohort at double the dose which started on 22nd April cant wait to see what sort of response we see with the addition of intraventricular (dual administration). And remember with no mandated stagger, it will be much quicker to results.

I've put (t)rolling on ignore too. Last time they will be acknowledged. Although, I'm sure there will be more but let's look at that as a compliment as there will be soon more eyes on CHM.